Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Sarcoma, Synovial 1Melanoma 1Advanced Fallopian Tube Carcinoma 1

Interventions

pembrolizumab 49Nivolumab 22Cyclophosphamide 20fludarabine 13Paclitaxel 9Ipilimumab 9atezolizumab 8aldesleukin 8Specimen Handling 8Interleukin-2 7Carboplatin 7Magnetic Resonance Spectroscopy 6Docetaxel 6Biopsy 6cemiplimab 5fludarabine phosphate 4durvalumab 4Taxes 4Gemcitabine 4Drug Therapy 4spartalizumab 3poly ICLC 3epacadostat 3X-Rays 3Leucovorin 3Injections 3Immunoglobulin G 3Filgrastim 3Cisplatin 3CTLA-4 Antigen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Leukapheresis × Gynecologic × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡